Superluminal Medicines Announces Oversubscribed $60 Million Series B Financing to Advance Lead Program in Rare Genetic Forms of Obesity into the Clinic

Summary

Superluminal Medicines closed an oversubscribed $60 million Series B financing round led by BVF Partners to advance its lead program for rare genetic forms of obesity toward clinical development. The round includes participation from multiple venture capital and strategic investors including Eli Lilly and Company.